secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001551152-23-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie updates 2023 EPS guidance to include $66M acquired IPR&D expense
-----------------------------------------------------------------------

- Q3 2023 acquired IPR&D & milestones expense of $66M pre-tax; reduces diluted EPS by $0.04.
- Updated Q3 2023 adjusted diluted EPS guidance: $2.76 - $2.86 (previously $2.80 - $2.90).
- Full-year 2023 adjusted diluted EPS guidance: $10.86 - $11.06 (previously $10.90 - $11.10).
- Prior guidance excluded Q3 2023 IPR&D expense; company does not forecast such expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000036/0001551152-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000036/abbv-20231004.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer